Oragenics OGEN shares are trading higher on Friday after the company discontinued its AG013 oral mucositis development program and said it will use available cash to continue the development of its TerraCoV2 coronavirus vaccine candidate.
Oragenics is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious disease and on developing effective treatments for oral mucositis.
Oragenics involves developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and have other product candidates, including SMaRT Replacement Therapy positioned for out-licensing or partnering.
Oragenics shares were trading up 32.57% at $1.28 at the time of publication on Friday. The stock has a 52-week high of $1.32 and a 52-week low of 35 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
